

ARTHUR ELLIS, CPA  
*Legislative District 28*  
Charles County

DEPUTY MAJORITY LEADER


Finance Committee  
Vice Chair, Rules Committee

*Senate Chair*  
Joint Committee on the  
Management of Public Funds

*Senate Chair*  
Joint Committee on  
Workers' Compensation Benefit and  
Insurance Oversight

Senate Chair, Charles County Delegation

Chair, Select Committee Southern  
Maryland



THE SENATE OF MARYLAND  
ANNAPOLIS, MARYLAND 21401

*Annapolis Office*  
James Senate Office Building  
11 Bladen Street, Room 301  
Annapolis, Maryland 21401  
410-841-3616  
800-492-7122 Ext. 3616  
Arthur.Ellis@senate.maryland.gov

*District Office*  
3261 Old Washington Road  
Waldorf, Maryland 20602

Sponsor Written Testimony: Favorable  
Senate Bill 0078: Public Health – Prostate-Specific Antigen Testing (Protect Our Prostate Act)

February 10, 2026

Chair Beidle, Vice Chair Hayes, and colleagues of the Senate Finance Committee:

I am pleased to sponsor and request a favorable report on this important public health legislation, which strengthens patient protections and promotes accurate, responsible use of prostate-specific antigen (PSA) testing in Maryland.

According to the American Cancer Society, “about 1 in 8 men will be diagnosed with prostate cancer during their lifetime,” and in the United States, an estimated “333,830 new cases” are expected in 2026.<sup>1</sup> The Centers for Disease Control and Prevention (CDC), and the National Cancer Institute suggests that PSA testing is widely used as a screening tool to help detect prostate cancer early, often before symptoms develop. Early detection through PSA testing can lead to timely intervention and improved outcomes for patients; however it is an imperfect tool. Unfortunately, false-positive results are common. About 6%–7% of men have a false-positive PSA test on any given screening round, and only about 25% of men who have a biopsy due to an elevated PSA level are found to have prostate cancer.<sup>2</sup> Because of these findings, there is an urgent need for integrating higher laboratory standards for patients receiving prostate-specific antigen testing.

By promoting standardized laboratory practices and enhanced patient education, Senate Bill 0078 aligns with the core principles of evidence-based screening. For these reasons, I respectfully urge the Senate Finance Committee to issue a favorable report on Senate Bill 0078.

Sincerely,

A handwritten signature in cursive script that reads "Arthur Ellis".

Arthur Ellis, CPA

<sup>1</sup> American Cancer Society. “Key Statistics for Prostate Cancer.” <https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html>

<sup>2</sup> Grubb RL 3rd, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Update on findings from the initial four rounds of screening in a randomized trial. *BJU International* 2008; 102(11):1524–1530.